Expert Interview
Discussing the recent ESMO data on Amgen's KRAS-G12C- inhibitor, sotorasi, from the CodeBreak 300 Phase 3 trial in mCRC
Ticker(s): AMGNThis expert has a clinical interest in metastatic colorectal cancer and their research interest in KRAS G12C-mutated cancers.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
